7.90Open7.90Pre Close0 Volume0 Open Interest11.50Strike Price0.00Turnover1770.01%IV14.89%PremiumApr 11, 2025Expiry Date7.27Intrinsic Value100Multiplier1DDays to Expiry0.63Extrinsic Value100Contract SizeAmericanOptions Type-0.6592Delta0.0816Gamma0.54Leverage Ratio-0.5938Theta-0.0003Rho-0.35Eff Leverage0.0009Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet